Background There is a high incidence of ventricular arrhythmia and sudden death in patients with heart failure. Unfortunately, currently available antiarrhythmic agents have only limited efficacy and may result in proarrhythmia and hemodynamic deterioration in these patients. Methods C ongestive heart failure is characterized by contractile dysfunction, frequent complex ventricular ectopy, and a high incidence of sudden death. Unfortunately, currently available antiarrhythmic agents have only limited efficacy in patients with congestive heart failure and may be associated with worsening ectopic activity and hemodynamic deterioration. Magnesium is a ubiquitous divalent cation that strongly influences cardiac cell membrane function and is an important catalyst of many enzymatic reactions in the myocyte. Alterations in extracellular or intracellular magnesium concentration could significantly influence the development and frequency of ventricular arrhythmia in patients with heart failure. These patients are predisposed to magnesium deficiency secondary to diuretic and digoxin administration, neurohormonal activation resulting in volume expansion, and poor oral intake and absorption.1 Ventricular arrhythmia may arise in heart failure as a result of enhanced automaticity or triggered activity. Experimental studies suggest that magnesium administration may reduce or prevent the occurrence of ventricular arrhythmia induced by these mechanisms. 23 A beneficial effect of magnesium on complex ventricular ectopy in patients with heart failure could have important consequences because this arrhythmia may culminate in ventricular fibrillation and sudden death.
Despite the potential for therapeutic benefit, there are few studies of the antiarrhythmic effect of parenteral magnesium in heart failure,4-8 and to the best of our knowledge, a randomized, placebo-controlled trial has not been performed. Therefore, we prospectively investigated the antiarrhythmic effect of acute magnesium infusion using a randomized, double-blind, placebo-controlled crossover design. Our hypothesis was that acute augmentation of serum magnesium concentration would reduce the frequency and severity of ventricular arrhythmia in patients with symptomatic congestive heart failure.
Methods

Eligibility and Exclusion
Study subjects were recruited prospectively by review of patients seen by the Heart Failure Program at the University of North Carolina at Chapel Hill. Inclusion criteria included age of 18 years or older, left ventricular ejection fraction .40% by radionuclide ventriculogram, presence of heart failure for at least 1 month, New York Heart Association (NYHA) class II to IV, and normal sinus rhythm. Exclusion criteria included a history of symptomatic ventricular ectopy, antiarrhythmic drug therapy (procainamide, quinidine, disopyramide, phenytoin, tocainide, mexiletine, ethmozine, flecainide, encainide, propafenone, amiodarone, sotalol), calcium channel antagonists, /3-blockers, a PR interval >0.2 seconds, or a serum creatinine >2 mg/dL. Digitalis use was not an exclusion criterion. The protocol was approved by the Institutional Review Board of the University of North Carolina School of Medicine, and written consent was obtained from all patients before study entry.
Study Design
This study was a randomized, double-blind, placebo-controlled crossover trial requiring 4 
Results
Study Patients
The protocol was successfully completed by 30 of the 35 patients who were enrolled. Incomplete Holter monitoring excluded 2 patients, and heart failure exacerbation before randomization excluded 2 other patients. One diabetic patient developed symptomatic hypoglycemia on the placebo day and was excluded from analysis. There were 21 men and 9 women aged 49±+-9.6 years (mean+SD). The etiology of heart failure was predominantly nonischemic. Heart failure was secondary to hypertension and/or alcohol abuse in 19 subjects (1 subject also had sarcoidosis) and to coronary artery disease in 4 and was idiopathic in 7 subjects. All 
Magnesium Administration
For the group as a whole, the preinfusion serum concentration of magnesium was higher on the placebo day compared with the magnesium day, 2.2±0.1 mg/dL versus 2.0±0.1 mg/dL, respectively (P=.037). In the 16 subjects given magnesium on day 2, the preinfusion serum concentration of magnesium was significantly higher on the placebo day than the magnesium day (2.2+0.1 mg/dL versus 2.0±0.1 mg/dL, P<.01). By contrast, preinfusion serum magnesium concentration was similar on the magnesium and placebo days (2.1+0.1 mg/dL versus 2.0±0.1 mg/dL, P=NS) when magnesium was given on day 4. The total dose of magnesium chloride administered was 163±33 mEq (mean+SD), with a range of 117 to 258 mEq. Fig 1 shows the serum concentration of magnesium before (time 0) and during the magnesium infusion. The serum magnesium concentration was significantly increased over the entire 24-hour infusion period, calculated as area under the curve (n= 14), compared with placebo (P=.001). Serum magnesium concentration was 3.6±0.1 mg/dL 30 minutes after the bolus (n=13) and 4.2±0.1 mg/dL after 24 hours (n=19) compared with placebo (P<.001).
The preinfusion serum concentration of potassium was 4.3±0.1 mmol/L (n=27) on the placebo and magnesium days. In a subset of patients, serum potassium concentrations were not significantly different at 30 minutes (n=8) or 24 hours (n=9) after magnesium infusion compared with placebo. There was also no significant difference between potassium concentration on the magnesium and placebo days calculated as area under the curve (n=8).
Magnesium and Ventricular Arrhythmia
The infusion of intravenous magnesium chloride significantly decreased the total number of PVCs per hour by 53% (70±26 versus 149+64, P<.001) compared with placebo (Fig 2) . More complex forms of ventricular arrhythmia were also reduced during magnesium infusion, including couplets per day by 76% (23 ± 
Discussion
Our study reports results of the first randomized, placebo-controlled trial to investigate the antiarrhythmic effect of acute parenteral magnesium administration on ventricular arrhythmia in patients with symptomatic heart failure. We found that magnesium infusion significantly reduced total ventricular ectopy, couplets, and episodes of ventricular tachycardia by 53%, 76%, and 69%, respectively. The rate of the fastest episode of ventricular tachycardia was also significantly decreased during magnesium administration. Serum magnesium concentration was substantially increased over the entire infusion period. The infusion was well tolerated. Magnesium administration produced no sustained effects on blood pressure or heart rate. A reduction in ventricular ectopy was observed even though the preinfusion magnesium concentration on the placebo day was higher than on the magnesium day, which could have diminished our ability to detect an antiarrhythmic effect of magnesium. Serum Previous Work There are limited data on the effect of magnesium on ventricular arrhythmia in patients with congestive heart failure. Dyckner and Wester4 infused 30 mmol magnesium sulfate over 10 hours in 33 patients suspected of being magnesium deficient, including 20 patients with congestive heart failure. Ventricular ectopy was significantly reduced during 3 hours of monitoring conducted 12 hours after magnesium administration. The effect of magnesium in the subjects with heart failure alone was not reported. Camara et a15 administered intramuscular magnesium to 3 patients hospitalized with heart failure caused by Chagas' disease. Episodes of nonsustained ventricular tachycardia were abolished, and ventricular ectopy was significantly reduced after magnesium administration. Frustaci et a16 reported that parenteral magnesium administration abolished ventricular tachycardia and reduced ventricular extrasystoles by 80% in 3 patients with dilated cardiomyopathy and in 1 patient with right ventricular dysplasia, all of whom had low myocardial magnesium concentrations. There was no effect in 4 patients who had myocarditis and normal myocardial magnesium concentrations. Perticone et a17 studied 10 patients with ischemic dilated cardiomyopathy and symptomatic ventricular tachycardia who had normal serum magnesium concentrations and were not taking diuretics. Intravenous administration of magnesium sulfate (6 g) daily for 1 week resulted in a significant reduction in the frequency of PVCs and couplets and abolished ventricular tachycardia by day 5. In contrast to the previous studies, Gottlieb et a18 conducted a non-placebo-controlled trial in 30 patients with symptomatic heart failure. They found no reduction in ventricular arrhythmia during 6 hours of monitoring after magnesium sulfate infusion (0.2 mEq/kg over 1 hour) compared with a similar baseline period 1 week previously.
Our study differs from this previous work in several important respects. None of the prior investigations were placebo-controlled studies. By contrast, our investigation was randomized, double-blind, and placebocontrolled. All patients had well-documented chronic congestive heart failure secondary to systolic dysfunction and were receiving an angiotensin-converting enzyme inhibitor and digoxin. None of the patients were receiving other antiarrhythmic agents, calcium channel antagonists, or 3-blockers that could have influenced the frequency of ventricular arrhythmia. The study was designed with a sufficient sample size and monitoring period to have the power to detect an antiarrhythmic effect of magnesium. Serum magnesium was also substantially increased, approximately twofold, over the entire infusion period.
Our data suggest that augmentation of serum magnesium concentration may result in an antiarrhythmic effect, independent of repletion of body stores. No carryover effect of magnesium infusion on the frequency of ventricular arrhythmia was evident when the placebo day followed the magnesium day. Furthermore, ventricular ectopy began to increase within several hours after completion of the magnesium infusion. This gradual increase in ventricular ectopy during the washout day as serum magnesium concentration was decreasing also suggests that the antiarrhythmic effect of magnesium may be dose related. A dose-response relation may help to reconcile the results of Gottlieb et a18 with our study. Our dosing regimen maintained a 100% increase in serum magnesium during monitoring compared with a 33% augmentation at the end of a 6-hour monitoring period in their study.
Two studies of oral magnesium supplementation have been reported. Gottlieb et al13 reported no effect of 8 weeks of oral magnesium chloride supplementation (128 mg TID as tolerated) compared with placebo on ventricular arrhythmia in 40 patients with congestive heart failure. Serum magnesium concentrations were not significantly changed at the end of treatment. In contrast, Bashir et 
Study Limitations
Certain limitations of the present study should be considered as the results are interpreted. Our clinical trial examined the acute antiarrhythmic effect of parenteral administration of magnesium chloride. Whether similar beneficial effects on ventricular arrhythmia would occur during chronic oral administration of magnesium independent of an effect on serum potassium is unknown. Our study also was not designed to assess the impact of magnesium administration on symptomatic ventricular arrhythmia or on the frequency of sudden death in patients with congestive heart failure. Additional studies of larger numbers of patients will be required to resolve these important issues.
Conclusions
Our study demonstrated that acute parenteral administration of magnesium chloride, in a dose that augments the serum concentration twofold, results in a significant reduction in ventricular arrhythmia in patients with symptomatic heart failure. Our results suggest that further investigation of the dose-response relation and the effect of chronic oral magnesium administration on ventricular arrhythmia in a larger population of patients with congestive heart failure is warranted.
